Myriad Genetics, Inc. provided revenue guidance for the first quarter 2024. For the quarter, the company expects revenue to grow at a mid-to-high single digit percentage rate year-over-year; and this growth rate is expected to accelerate throughout the rest of the year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.47 USD | +0.87% | +30.82% | +33.07% |
May. 08 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
May. 08 | Myriad Genetics Shares Rise After Reporting Narrower Q1 Adjusted Loss, Higher Revenue | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.07% | 2.31B | |
-1.29% | 12.64B | |
-0.47% | 8.46B | |
+22.61% | 5.27B | |
-2.03% | 4.49B | |
-53.56% | 3.11B | |
+19.30% | 2.87B | |
-8.42% | 2.23B | |
-3.55% | 1.89B | |
+5.37% | 1.64B |
- Stock Market
- Equities
- MYGN Stock
- News Myriad Genetics, Inc.
- Myriad Genetics, Inc. Provides Revenue Guidance for the First Quarter 2024